AI assistant
ATAI Life Sciences N.V. — Director's Dealing 2021
Jun 18, 2021
32049_dirs_2021-06-17_edcc4ca7-3e08-4df3-9d47-984b2558bd25.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: ATAI Life Sciences B.V. (ATAI)
CIK: 0001840904
Period of Report: 2021-06-17
Reporting Person: Apeiron Investment Group Ltd. (10% Owner)
Reporting Person: Presight II, LP (10% Owner)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Shares | 19485200 | Indirect |
| Common Shares | 1187104 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Convertible Notes | $ | Common Shares (8320000) | Indirect |
Footnotes
F1: 1. Apeiron Investment Group Ltd. is the co-managing member of Presight Capital Management I, LLC, which is the general partner of Presight II, L.P. Therefore, Apeiron Investment Group Ltd. may be deemed to share beneficial ownership of the Common Shares held by Presight II, L.P. Apeiron Investment Group Ltd. is owned and controlled by Christian Angermayer. Mr. Angermayer may be deemed to have beneficial ownership over the shares held by Apeiron Investment Group Ltd. and Presight II, L.P.
F2: The Convertible Notes are currently exercisable and will mature on September 30, 2025.
F3: The conversion price for the Convertible Notes is Euro 17.00 per share.